Navigation Links
Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Date:11/13/2013

treat significant ocular disorders such as corneal defects and ulcers. He is well known and respected both in the Salt Lake City area and nationally for his entrepreneurial and company-building achievements, and he has served on the Boards of numerous start-up life sciences companies."

Said Dr. Patel: "Jade represents an attractive combination of proprietary, lower-risk products addressing unmet needs in potentially blinding ophthalmic conditions. I look forward to working with the Company's Board and management team to help bring these products to the patients who need them."

About Jade Therapeutics

Jade Therapeutics, founded by Drs. Barbara Wirostko and MaryJane Rafii, is a privately held company headquartered in Salt Lake City, Utah, that develops locally administered, sustained-release formulations of (mostly) already-approved drugs for use in poorly served ophthalmic indications. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual function with enhanced quality of life.  Jade believes that its use of proprietary administration formulations of drugs that have already received regulatory approval may significantly decrease development risks and shorten the clinical trial and regulatory approval process. Jade's lead programs focus on delivering (1) recombinant human growth hormone to help address persistent corneal epithelial defects, and (2) antibiotics to treat bacterial keratitis and corneal ulcers (utilizing funding from a recently awarded National Science Foundation SBIR grant). For additional information about Jade, please visit www.jadetherapeutics.com

Contact:
'/>"/>

SOURCE Jade Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... company overview at the Nomura Biotechnology Conference on Thursday, November ... MA. A live webcast of the ... of the Company,s website, www.isispharm.com .  A replay will ... will be archived for a limited time. About ...
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... and TORONTO , Oct. 27, ... ) (OTCQB: GNBT) today announced two presentations demonstrating ... by its novel proprietary cancer immunotherapeutic AE37 vaccine ... cancer patients. The AE37 cancer vaccine is being ... Inc. ( www.antigenexpress.com ). The presentations are being ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... and GERMANTOWN, Maryland, May 3, 2012 ... assay to detect rupture of fetal membranes (ROM)   - ... Novel FDA-cleared test is highly synergistic with ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today announced ...
... ANGELES, May 3, 2012 MD+DI ( ... brand providing the medical device industry with the latest news ... for Best Cover in the Medical, Dental & Related ... May 2011 cover was also a finalist for the ...
... Corporation (Nasdaq: VRNM ), a leading industrial biotechnology ... today announced that it will release 2012 first ... close. In conjunction with the release, the Company will host ... at 5:00 p.m. ET. The call may be ...
Cached Biology Technology:QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 2QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 3QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 4QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 5MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category 2Verenium Corporation To Announce First Quarter 2012 Financial Results 2
(Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... Virology group at the Institute for Molecular Medicine Finland ... national and international collaborators, developed a new cell screening ... drugs. The researchers were able to identify two novel ... the efficacy of a previously known drug saliphenylhalamide. ...
... to discontinue in 2013 a unique environmental research project that ... topics for almost 40 years would be a "huge loss ... humanity." That,s the focus of a viewpoint article in ACS, ... Hering, D. L. Swackhamer and W. H. Schlesinger explain that ...
... on the Florida campus of The Scripps Research Institute have ... for one of the diseases closely linked to fragile X ... memory impairment, and is the only known single-gene cause of ... the journal ACS Chemical Biology September 4, 2012, ...
Cached Biology News:Harnessing anticancer drugs for the future fight against influenza 2Scripps Florida scientists design molecule that reverses some fragile X syndrome defects 2
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
... Source: Escherichia coli RY 13 5'G AATTC3' 3'CTTAA ... 15 min or ethanol precipitation. Storage Conditions: 10mM ... DTT, 0.15% Triton X-100, 0.01% BSA, 50% glycerol. ... at -20C. Unit Definition: One unit is defined ...
... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
ANTI DIPHTH TOX A SU...
Biology Products: